Regencell Bioscience Holdings Limited, a herbal medicine biotech firm, has experienced an astonishing 46,000% surge in its stock value in 2025, despite generating no revenue since its inception. This Hong Kong-based company, specializing in traditional Chinese medicine for neurological conditions, saw its market capitalization soar to $30 billion.
Related Posts
Maha Kumbh stampede: VIPs to pick ‘non-snan’ days
The stampede at Maha Kumbh offered a chance to opposition parties to criticize the BJP govt’s handling of the event, alleging mismanagement and VIP focus. […]
‘No guarantees of assured returns’: Sebi warns investors about stock ‘games’, virtual trades
India’s market regulator, SEBI, issued a warning to investors about unauthorized entities offering virtual trading services and fantasy games based on stock prices. These platforms […]